HUP0002426A2 - Oldékony interleukin-6-receptor/ligandum kiméraprotein és analógjai, valamint ezek alkalmazási eljárásai - Google Patents

Oldékony interleukin-6-receptor/ligandum kiméraprotein és analógjai, valamint ezek alkalmazási eljárásai

Info

Publication number
HUP0002426A2
HUP0002426A2 HU0002426A HUP0002426A HUP0002426A2 HU P0002426 A2 HUP0002426 A2 HU P0002426A2 HU 0002426 A HU0002426 A HU 0002426A HU P0002426 A HUP0002426 A HU P0002426A HU P0002426 A2 HUP0002426 A2 HU P0002426A2
Authority
HU
Hungary
Prior art keywords
sil
protein
chimeric
vector
naturally occurring
Prior art date
Application number
HU0002426A
Other languages
English (en)
Inventor
Judith Chebath
Orit Kollet
Tsvee Lapidot
Michel Revel
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0002426(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL12128497A external-priority patent/IL121284A0/xx
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of HUP0002426A2 publication Critical patent/HUP0002426A2/hu
Publication of HUP0002426A3 publication Critical patent/HUP0002426A3/hu
Publication of HU225855B1 publication Critical patent/HU225855B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgya az interleukin-6 (IL-6) biológiai aktivitásaivalfügg össze, melyek az oldható IL-6-receptor (sIL-6R) agonistaműködésével kapcsolatosak. Közelebbről, a találmány tárgyát olyan sIL-6R/IL-6-kiméraproteinek képezik, amelyek lényegében az sIL-6R és IL-6természetben előforduló alakja (illetve biológiailag aktív analógjaik)fuzionáltatásával vannak előállítva. Szintén a találmány tárgyátképezik a találmány szerinti kiméraproteineket kódoló DNS-szekvenciák,a találmány szerinti DNS-eket hordozó vektorok, a találmány szerintivektorokkal transzformált gazdasejtek, valamint eljárások a találmányszerinti kiméraproteinek előállítására és alkalmazására. A találmányszerinti kiméraproteinek (a rákos sejtek szaporodásának gátlása révén)különösen előnyösen alkalmazhatók rák kezelésére, továbbá csontvelő-átültetés hatékonyságának fokozására, májbetegségek kezelésére,valamint egyéb, IL-6-tal összefüggő állapotok kezelésére. Ó
HU0002426A 1997-07-10 1998-07-09 Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof HU225855B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12128497A IL121284A0 (en) 1997-07-10 1997-07-10 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL12281897A IL122818A0 (en) 1997-07-10 1997-12-30 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
PCT/IL1998/000321 WO1999002552A2 (en) 1997-07-10 1998-07-09 Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Publications (3)

Publication Number Publication Date
HUP0002426A2 true HUP0002426A2 (hu) 2000-11-28
HUP0002426A3 HUP0002426A3 (en) 2003-01-28
HU225855B1 HU225855B1 (en) 2007-11-28

Family

ID=26323470

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002426A HU225855B1 (en) 1997-07-10 1998-07-09 Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Country Status (27)

Country Link
US (2) US7198781B1 (hu)
EP (1) EP0991661B1 (hu)
JP (1) JP4402288B2 (hu)
KR (1) KR100505172B1 (hu)
CN (1) CN1185348C (hu)
AR (1) AR013201A1 (hu)
AT (1) ATE342915T1 (hu)
AU (1) AU758161B2 (hu)
BG (1) BG64680B1 (hu)
BR (1) BR9812096B1 (hu)
CA (1) CA2295936C (hu)
CY (1) CY1105895T1 (hu)
CZ (1) CZ302488B6 (hu)
DE (1) DE69836217T2 (hu)
DK (1) DK0991661T3 (hu)
EA (1) EA004793B1 (hu)
EE (1) EE05519B1 (hu)
ES (1) ES2271999T3 (hu)
HK (1) HK1031895A1 (hu)
HU (1) HU225855B1 (hu)
IL (2) IL122818A0 (hu)
NO (1) NO327397B1 (hu)
NZ (1) NZ502139A (hu)
PL (1) PL199212B1 (hu)
PT (1) PT991661E (hu)
SK (1) SK287039B6 (hu)
WO (1) WO1999002552A2 (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
DE69941406D1 (de) * 1998-07-06 2009-10-22 Tosoh Corp IL-6 Rezeptor IL-6-gekoppeltes Fusionsprotein
CN101575377B (zh) * 1999-03-09 2012-12-26 津莫吉尼蒂克斯公司 作为zalpha受体之配体的人细胞因子及其用途
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
CA2447632C (en) 2000-06-16 2011-08-02 Asterion Limited Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor
DE60119347T2 (de) * 2000-09-14 2007-02-22 Ares Trading S.A. Verwendung von chimäres il6-il6r in huntingtonskrankheit
DE10106827A1 (de) * 2001-02-14 2002-09-05 Stefan Rose-John Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L)
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
GB2389115B (en) * 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
EP1499332A4 (en) * 2002-04-29 2006-12-06 Hadasit Med Res Service COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A VIRAL ONCOLYTIC AGENT
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
FR2850621B1 (fr) * 2003-02-04 2006-12-08 Journee Paul Connecteur reliant un bras d'essuie-glace a un balai d'essuyage, qui comporte deux languettes pour le verrouillage transversal de bras d'essuie-glace
DE10321317A1 (de) * 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
IL159558A0 (en) * 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2006286149B2 (en) 2005-08-29 2012-09-13 Technion Research And Development Foundation Ltd. Media for culturing stem cells
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
JP2009543579A (ja) * 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
DK2733203T3 (en) * 2006-08-02 2019-02-04 Technion Res & Dev Foundation PROCEDURES FOR EXPANSION OF EMBRYONAL STEM CELLS IN A SUSPENSION CULTURE
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
JP5213075B2 (ja) * 2007-06-15 2013-06-19 ジェネラックス・コーポレイション 腫瘍の画像化および／または処置のための微生物
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
CN101827857A (zh) * 2007-08-03 2010-09-08 埃斯特瑞恩有限公司 粒细胞集落刺激因子
US20110177070A1 (en) * 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
MX2011000071A (es) * 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
WO2010081738A1 (en) 2009-01-16 2010-07-22 Agirx Limited Vaccine compositions
ES2779048T3 (es) 2009-11-12 2020-08-13 Technion Res & Dev Foundation Medios de cultivo, cultivos celulares y métodos de cultivo de células madre pluripotentes en un estado indiferenciado
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
SG10201800628QA (en) 2010-09-07 2018-02-27 Technion Res & Dev Foundation Novel Methods And Culture Media For Culturing Pluripotent Stem Cells
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
KR20150145260A (ko) 2013-04-19 2015-12-29 싸이튠 파마 감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료
WO2015023505A1 (en) * 2013-08-12 2015-02-19 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of interest and il6
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104826093A (zh) * 2015-04-16 2015-08-12 刘永庆 用于治疗慢性传染性肝病的Th2免疫反应拮抗剂及卵黄抗体
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2022256688A1 (en) 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
PL190445B1 (pl) * 1995-05-15 2005-12-30 Akademia Medyczna Im K Marcink Genetyczna szczepionka przeciwrakowa
DE19608813C2 (de) * 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
CA2311648C (en) * 1997-12-19 2010-11-16 Applied Research Systems Ars Holding N.V. Ifnar2/ifn complex

Also Published As

Publication number Publication date
NO20000086D0 (no) 2000-01-07
US7374912B2 (en) 2008-05-20
HUP0002426A3 (en) 2003-01-28
CN1269835A (zh) 2000-10-11
EP0991661A2 (en) 2000-04-12
CA2295936A1 (en) 1999-01-21
NO20000086L (no) 2000-03-08
NZ502139A (en) 2002-03-28
DE69836217D1 (de) 2006-11-30
HU225855B1 (en) 2007-11-28
US7198781B1 (en) 2007-04-03
US20070172455A1 (en) 2007-07-26
DE69836217T2 (de) 2007-08-23
DK0991661T3 (da) 2007-02-05
CZ200075A3 (cs) 2000-08-16
KR100505172B1 (ko) 2005-08-03
AU758161B2 (en) 2003-03-20
ES2271999T3 (es) 2007-04-16
IL133972A (en) 2015-07-30
CY1105895T1 (el) 2011-02-02
CN1185348C (zh) 2005-01-19
BR9812096B1 (pt) 2011-09-06
AR013201A1 (es) 2000-12-13
EP0991661B1 (en) 2006-10-18
AU8127198A (en) 1999-02-08
JP4402288B2 (ja) 2010-01-20
BG64680B1 (bg) 2005-11-30
WO1999002552A2 (en) 1999-01-21
HK1031895A1 (en) 2001-06-29
PL199212B1 (pl) 2008-08-29
BG104070A (en) 2000-11-30
EA200000109A1 (ru) 2000-08-28
EE05519B1 (et) 2012-02-15
EA004793B1 (ru) 2004-08-26
CZ302488B6 (cs) 2011-06-15
NO327397B1 (no) 2009-06-22
KR20010021522A (ko) 2001-03-15
BR9812096A (pt) 2000-07-18
SK287039B6 (sk) 2009-10-07
WO1999002552A3 (en) 1999-04-01
PT991661E (pt) 2007-01-31
PL338002A1 (en) 2000-09-25
SK62000A3 (en) 2000-07-11
EE200000012A (et) 2000-08-15
CA2295936C (en) 2009-05-26
JP2001509371A (ja) 2001-07-24
IL122818A0 (en) 1998-08-16
ATE342915T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
HUP0002426A2 (hu) Oldékony interleukin-6-receptor/ligandum kiméraprotein és analógjai, valamint ezek alkalmazási eljárásai
HUP0000317A3 (en) Process for the preparation of recombinant proteins in e.coli by high cell density fermentation
IE820069L (en) Recombinant dna encoding a polypeptide
EP0790255A3 (en) Cytotoxic lymphocyte maturation factor and monoclonal antibodies directed thereto
NO914387D0 (no) Fremstilling av hemoglobin og dens analoger i bakterier og gjaer
EP0088195A3 (en) Messenger rna, production and use thereof
EP0318296A3 (en) Interleukin-1 receptors
IL98205A0 (en) Type ii interleukin-1 receptors
AU9084601A (en) G-csf analog compositions and methods
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
DE68929402T2 (de) Verfahren zur herstellung von wasserlöslichen polypeptiden
WO2004098530A3 (en) Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
HK1014198A1 (en) Improved methods for the preparation of endotoxin-binding proteins
EP0366016A3 (en) Endothelin dna and use thereof
IL88151A0 (en) Interleukin-7,its preparation and compositions containing it
HU904957D0 (en) Parenchymal liver call growth factor, the gene coding this and process for producing transformants creating this factor
CA2011833A1 (en) Novel polypeptide and production thereof
EP0123928A3 (en) Recombinant dna coding for a polypeptide displaying milk clotting activity
WO1992001782A3 (fr) Sucrose phosphate synthetase (sps), son procede de preparation, son adn complementaire et l'utilisation de l'adn complementaire pour modifier l'expression de la sps dans les cellules vegetales
CA2011378A1 (en) Achromobacter protease i gene and gene product thereof
NZ296562A (en) Recombinant peptides and secretory mehods for their preparation
CA2052396A1 (en) Synthetic gene coding for human parathyroid hormone
CA2051010A1 (en) Human luteinizing hormone-chorionic gonadotropin receptor protein, dna and use thereof
CA2006587A1 (en) Membrane proteins and peptides of haemophilus influenzae type b
WO2002016584A3 (en) Process for the preparation of neutrophil inhibitory factor

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees